SAN
DIEGO, May 16, 2024 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
the promotion of Rekha Garg, M.D.,
M.S., to Chief Medical Officer effective May
16, 2024. Dr. Garg previously served as the Company's Senior
Vice President, Clinical Development and Regulatory.
"Dr. Garg has been leading the development and regulatory teams
since joining Regulus in 2022," said Jay
Hagan, Chief Executive Officer of Regulus Therapeutics. "Her
dedication to the Company and the advancement of RGLS8429 has been
outstanding and she will continue to play a key role in this new
position as our program progresses."
"It's an honor to become Chief Medical Officer and I'm excited
to have this unique opportunity to make a meaningful impact on
patients with ADPKD, a disease with significant unmet need," said
Rekha Garg, Chief Medical Officer.
"I look forward to advancing our program through the next stages of
clinical development in partnership with the rest of the leadership
team."
Dr. Garg is a physician executive with over 20 years of
experience in leadership roles in the biopharma industry, across
multiple therapeutic areas including kidney disease. Before joining
Regulus, she was Senior Vice President, Regulatory Affairs and
Safety, at Sanifit Therapeutics. Prior to that, she was Vice
President at Infinity Pharmaceuticals and served in multiple
leadership roles in clinical development, regulatory affairs, and
risk management at Amgen and Eli Lilly. Prior to joining the
pharmaceutical industry, she held a similar role at the National
Heart, Lung, and Blood Institute. Dr. Garg received her B.A. in
Biology from Oberlin College, her M.D.
from the Medical College of Ohio and
completed her residency at the University of
Maryland School of Medicine where she also received an M.S.
in Epidemiology.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS)
is a biopharmaceutical company focused on the discovery and
development of innovative medicines targeting microRNAs. Regulus
has leveraged its oligonucleotide drug discovery and development
expertise to develop a pipeline complemented by a rich intellectual
property estate in the microRNA field. Regulus maintains its
corporate headquarters in San Diego,
CA.
Forward-Looking Statements
Statements contained in
this presentation regarding matters that are not historical facts
are "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
associated with the Company's RGLS8429 program, the expected timing
for initiating clinical studies, potentially achieving therapeutic
efficacy and clinical translation for ADPKD patients, the expected
timing for reporting topline data, the timing and future occurrence
of other preclinical and clinical activities and the expected
length of our cash runway. Because such statements are subject to
risks and uncertainties, actual results may differ materially from
those expressed or implied by such forward-looking statements.
Words such as "believes," "anticipates," "plans," "expects,"
"intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the approach we
are taking to discover and develop drugs is novel and may never
lead to marketable products, preliminary or initial results may not
be indicative of future results, preclinical and clinical studies
may not be successful, risks related to regulatory review and
approval, risks related to our reliance on third-party
collaborators and other third parties, risks related to
intellectual property, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and the risk additional
toxicology data may be negative and our need for additional
capital. These and other risks are described in additional detail
in Regulus' filings with the Securities and Exchange Commission,
including under the "Risk Factors" heading of Regulus' most
recently filed quarterly report on Form 10-Q. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Regulus undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-promotion-of-rekha-garg-md-ms-to-chief-medical-officer-302147030.html
SOURCE Regulus Therapeutics Inc.